Apr 10, 2021 2:15pm EDT Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at 2021 AACR Annual Meeting
Mar 30, 2021 7:00am EDT Pieris Pharmaceuticals Reports Full-Year 2020 Financial Results and Provides Corporate Update
Mar 25, 2021 8:00am EDT Pieris Announces Amendment of Existing Immuno-oncology Multi-target Collaboration with Seagen, a Clinical Trial and Supply Agreement to Evaluate Cinrebafusp Alfa (PRS-343) in Combination with TUKYSA® (tucatinib) in Gastric Cancer, and Strategic Equity Investment by Seagen
Mar 23, 2021 8:00am EDT Pieris Pharmaceuticals to Host Full-Year 2020 Investor Call and Provide Corporate Update on March 30, 2021
Feb 23, 2021 8:00am EST Pieris Pharmaceuticals to Participate in the Cowen 41st Annual Health Care Conference
Nov 04, 2020 7:00am EST Pieris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Oct 28, 2020 8:00am EDT Pieris Pharmaceuticals to Host Third Quarter 2020 Investor Call and Corporate Update on November 4, 2020
Sep 20, 2020 11:00am EDT Pieris Pharmaceuticals Presents Updated Data from Phase 1 Monotherapy and Atezolizumab Combination Studies of 4-1BB/HER2 Bispecific PRS-343 at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
